When human brain microvascular endothelial cells are treated with Aβ, they show increased expression of CXCR2 and this interaction with CXCL1 contributes to the disruption of the blood-brain barrier (BBB) and enhances the migration of monocytes into the brain in AD patients [86]. This evidence concerns the gene CXCR2 and Alzheimer disease.